Avantium announced that the capacity of that plant, which is to be started up in 2023, will be lower than the initial plans for a joint production location with chemical giant BASF. Avantium previously owned Synvina together with BASF, but the German chemical group withdrew from the joint venture established for the marketing of innovative chemical technology. According to KBC, the new production location is potentially good for a turnover of 25 million euros. With this, it can contribute up to 5 million euros to the annual operating result. KBC does think that Avantium still has to hold its hand with investors. The chemical company would have financial resources until the end of 2021. However, according to experts, it is unclear how Avantium closes the period until it becomes profitable without additional financing. For that reason, KBC Avantium continues to consider a risky investment. ING analysts believe that the smaller plant leads to a slower commercialization of bioplastics. However, this disadvantage does not outweigh the advantage of a factory that is wholly owned by Avantium for the bank’s market researchers. KBC maintained the reduce advice with a price target of 1.75 euros. ING has a buy recommendation with a price target of 12.90 euros. The Avantium share was listed on Friday around 10.00 am 0.4 percent higher at 2.38 euros.